CVS Specialty Savings Come at Members’ Expense
CVS recently released its a Drug Trend Report for 2021. Caremark found that 35.9% of its clients saw negative specialty trend in 2021. In addition, 65.3% saw
August 4, 2022
CVS recently released its a Drug Trend Report for 2021. Caremark found that 35.9% of its clients saw negative specialty trend in 2021. In addition, 65.3% saw
Walgreens continues to morph into a diverse health services company. The headline of the article below isn’t the real news. Rather, the article below lists
Curiouser and curiouser…….Over the past three years the three largest PBMs each formed a GPO to, in their words, “capitalize on scale to get better
We’ve been watching the slow but steady growth of value based contracting (VBCs) for some years now. Conceptually VBCs make a lot of sense. Payors
Fins to the left of me…… fins to the right….. and I’m the only PBM in town….(with apologies to Jimmy Buffet) What we are really
Last week we sent two reports highlighting the increasing pressure on PBMs in response to onerous business practices. The first described action being taken in
Earlier this week we issued a report on PBM business practices coming under increased scrutiny at the federal level. Well, the bullseye is not limited
PBMs continue to be under the microscope. The scrutiny comes on the heels of the FTC announcing that it was reversing its decision to shelf taking
Biosimilars are still struggling to gain maximum traction in the marketplace….. and a recent survey says that communications are at the heart of the problem.
June 28, 2022Winter Garden, FLThe FDA recently approved a new sub-cutaneous, specialty therapy, Amvuttra (vutrisiran) from Alnylam Pharmaceuticals, for the treatment of the polyneuropathy of
